Panitumumab

Panitumumab (INN), ranije -{ABX-EGF}-, je potpuno humanizovano monoklonalno antitelo koje je specifično za receptor epidermalnog faktora rasta (takođe poznat kao EGF receptor, EGFR, ErbB-1 i HER1 kod čoveka).Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. -{Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. . Epub 2007 Mar 13. }--{Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. .. }-

Reference

Literatura

Spoljašnje veze

-{Panitumumab}-

Категорија:Хемотерапијски агенси